Long-term effects of radioiodine treatment on thyroid functions and ultrasonographic features in patients with toxic adenoma and toxic multinodular goitre.
Nodule volume
Radioiodine treatment
TMNG
Thyroid ultrasonography
Toxic adenoma
Journal
Annals of nuclear medicine
ISSN: 1864-6433
Titre abrégé: Ann Nucl Med
Pays: Japan
ID NLM: 8913398
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
19
01
2023
accepted:
13
03
2023
medline:
22
5
2023
pubmed:
4
4
2023
entrez:
3
4
2023
Statut:
ppublish
Résumé
This study aimed to investigate the long-term effect of radioiodine (RAI) treatment on thyroid functions and ultrasonographic changes in the thyroid gland and toxic nodules. Thyroid function tests and ultrasonography reports of patients diagnosed with toxic adenoma (TA) or toxic multinodular goitre (TMNG) between 2000 and 2021 were retrospectively analysed. We included 100 patients whom thyroid function and ultrasonography results were obtained from our outpatient clinic before and at least 36 months post-RAI. At the end of the follow-up period, the mean thyroid volume reduction in patients with TA and TMNG was 56.6% ± 3.1% and 51.1% ± 6.7%, respectively; the mean volume decrease of all toxic nodules was 80.5% ± 1.9%. The volume of the thyroid and toxic nodules was significantly reduced up to 12 years (p < 0.01). Between 3 and 10 years after RAI therapy, the annual incidence of hypothyroidism was 2.0% and 1.5% in the TA and TMNG groups, respectively. Toxic nodules were more frequently solid and hypoechoic in post-RAI ultrasounds (p < 0.01). The volume of thyroid gland and toxic nodules continuously decreases, as the risk of hypothyroidism increases up to 10 years after RAI treatment. After RAI treatment, patients should be followed up to check their thyroid functions. In post-RAI examinations, toxic nodules may show ultrasonographic features suspicious for malignancy. History taking should include previous RAI therapies and old scintigraphy scans should be evaluated to avoid unnecessary procedures and non-diagnostic biopsy results.
Identifiants
pubmed: 37010726
doi: 10.1007/s12149-023-01834-z
pii: 10.1007/s12149-023-01834-z
doi:
Substances chimiques
Iodine Radioisotopes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
371-379Informations de copyright
© 2023. The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine.
Références
Brent GA. Clinical practice. Graves’ disease. N Engl J Med. 2008;358:2594–605.
doi: 10.1056/NEJMcp0801880
pubmed: 18550875
Vitti P, Rago T, Tonacchera M, Pinchera A. Toxic multinodular goiter in the elderly. J Endocrinol Invest. 2002;25:16–8.
pubmed: 12508907
Garmendia Madariaga A, Santos Palacios S, Guillén-Grima F, Galofré JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab. 2014;99:923–31.
doi: 10.1210/jc.2013-2409
pubmed: 24423323
Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): national health and nutrition examination survey (NHANES III). J Clin Endocrinol Metab. 2002;87:489–99.
doi: 10.1210/jcem.87.2.8182
pubmed: 11836274
Siegel RD, Lee SL. Toxic nodular goiter. Toxic adenoma and toxic multinodular goiter. Endocrinol Metab Clin North Am. 1998;27:151–68.
doi: 10.1016/S0889-8529(05)70304-2
pubmed: 9534034
Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G. High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves’ disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med. 1991;229:415–20.
doi: 10.1111/j.1365-2796.1991.tb00368.x
pubmed: 2040867
Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26:1343–421.
doi: 10.1089/thy.2016.0229
pubmed: 27521067
Bonnema SJ, Hegedüs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012;33:920–80.
doi: 10.1210/er.2012-1030
pubmed: 22961916
Roque C, Santos FS, Pilli T, Dalmazio G, Castagna MG, Pacini F. Long-term effects of radioiodine in toxic multinodular goiter: thyroid volume, function, and autoimmunity. J Clin Endocrinol Metab. 2020. https://doi.org/10.1210/clinem/dgaa214 .
doi: 10.1210/clinem/dgaa214
pubmed: 32812038
pmcid: 7494238
Nygaard B, Hegedüs L, Nielsen KG, Ulriksen P, Hansen JM. Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules. Clin Endocrinol (Oxf). 1999;50:197–202.
doi: 10.1046/j.1365-2265.1999.00635.x
pubmed: 10396362
Massaro F, Vera L, Schiavo M, Lagasio C, Caputo M, Bagnasco M, et al. Ultrasonography thyroid volume estimation in hyperthyroid patients treated with individual radioiodine dose. J Endocrinol Invest. 2007;30:318–22.
doi: 10.1007/BF03346299
pubmed: 17556869
Schenke SA, Wuestemann J, Zimny M, Kreissl MC. Ultrasound assessment of autonomous thyroid nodules before and after radioiodine therapy using thyroid imaging reporting and data system (TIRADS). Diagnostics (Basel). 2020;10:1038.
doi: 10.3390/diagnostics10121038
pubmed: 33276695
Stokkel MP, Handkiewicz Junak D, Lassmann M, Dietlein M, Luster M. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2010;37:2218–28.
doi: 10.1007/s00259-010-1536-8
pubmed: 20625722
Erdoğan MF, Küçük NO, Anil C, Aras S, Ozer D, Aras G, et al. Effect of radioiodine therapy on thyroid nodule size and function in patients with toxic adenomas. Nucl Med Commun. 2004;25:1083–7.
doi: 10.1097/00006231-200411000-00003
pubmed: 15577585
Stachura A, Gryn T, Kałuża B, Budlewski T, Franek E. Predictors of euthyreosis in hyperthyroid patients treated with radioiodine (131)I(-): a retrospective study. BMC Endocr Disord. 2020;20:77.
doi: 10.1186/s12902-020-00551-2
pubmed: 32487052
pmcid: 7268615
Tarantini B, Ciuoli C, Di Cairano G, Guarino E, Mazzucato P, Montanaro A, et al. Effectiveness of radioiodine (131-I) as definitive therapy in patients with autoimmune and non-autoimmune hyperthyroidism. J Endocrinol Invest. 2006;29:594–8.
doi: 10.1007/BF03344157
pubmed: 16957406
Reschini E, Castellani M, Gerundini P. Antithyroid treatment changes thyroid scintigraphy in autonomous thyroid adenoma. Thyroid. 2003;13:223–4.
doi: 10.1089/105072503321319558
pubmed: 12699599
Santos RB, Romaldini JH, Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves’ disease. Thyroid. 2004;14:525–30.
doi: 10.1089/1050725041517093
pubmed: 15307942
Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ. 2007;334:514.
doi: 10.1136/bmj.39114.670150.BE
pubmed: 17309884
pmcid: 1819480
Ceccarelli C, Bencivelli W, Vitti P, Grasso L, Pinchera A. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years’ retrospective study. Clin Endocrinol (Oxf). 2005;62:331–5.
doi: 10.1111/j.1365-2265.2005.02218.x
pubmed: 15730415
Boelaert K, Syed AA, Manji N, Sheppard MC, Holder RL, Gough SC, et al. Prediction of cure and risk of hypothyroidism in patients receiving 131I for hyperthyroidism. Clin Endocrinol (Oxf). 2009;70:129–38.
doi: 10.1111/j.1365-2265.2008.03291.x
pubmed: 18462261
Vija Racaru L, Fontan C, Bauriaud-Mallet M, Brillouet S, Caselles O, Zerdoud S, et al. Clinical outcomes 1 year after empiric 131I therapy for hyperthyroid disorders: real life experience and predictive factors of functional response. Nucl Med Commun. 2017;38:756–63.
doi: 10.1097/MNM.0000000000000705
pubmed: 28719405
Rokni H, Sadeghi R, Moossavi Z, Treglia G, Zakavi SR. Efficacy of different protocols of radioiodine therapy for treatment of toxic nodular goiter: systematic review and meta-analysis of the literature. Int J Endocrinol Metab. 2014;12: e14424.
doi: 10.5812/ijem.14424
pubmed: 24803943
pmcid: 4005974
Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol (Oxf). 2004;61:641–8.
doi: 10.1111/j.1365-2265.2004.02152.x
pubmed: 15521969
Kitahara CM, Preston DL, Sosa JA, de Gonzalez AB. Association of radioactive iodine, antithyroid drug, and surgical treatments with solid cancer mortality in patients with hyperthyroidism. JAMA Netw Open. 2020;3:e209660.
doi: 10.1001/jamanetworkopen.2020.9660
pubmed: 32701159
pmcid: 7378755